Veradermics, Inc Increase (Decrease) in Accrued Liabilities
Veradermics, Inc (MANE) reported Increase (Decrease) in Accrued Liabilities of -$1.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11
- Veradermics, Inc increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$211.00K, a 113.49% decline year-over-year.
- Veradermics, Inc increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.37M.
- Veradermics, Inc increase (decrease) in accrued liabilities for the quarter ending 2025-06-30 was $1.56M.
- Veradermics, Inc increase (decrease) in accrued liabilities for the quarter ending 2025-03-31 was -$862.00K.
- Veradermics, Inc increase (decrease) in accrued liabilities for fiscal 2025 was $4.51M, a 254.84% increase from fiscal 2024.
- Veradermics, Inc increase (decrease) in accrued liabilities for fiscal 2024 was $1.27M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|
| 2026-06-30 | -$211.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.58M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$1.37M 10-Q · filed 2026-05-12 | ||
| 2025-12-31 | $4.51M 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $702.00K 10-Q · filed 2026-08-11 | |
| 2025-03-31 | -$862.00K 10-Q · filed 2026-05-12 | ||
| 2024-12-31 | $1.27M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |